†These authors contributed equally.
Adoptive chimeric antigen receptor (CAR) T cells designed to recognize specific
tumor antigens have shown promising results in cancer therapy. While CAR T cell
therapy has demonstrated notable clinical effectiveness for hematologic disease,
efforts to develop therapies for solid tumors, including glioblastoma (GBM), have
been hampered by heterogeneity, an immunosuppressive tumor microenvironment, and
difficulty in trafficking. Several specific tumor antigens, such as